Emerging drugs for hemophilia B

Bibliography

• Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326(12):800-6
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012;7:24
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Pasi KJ. Haemophilia A and B. Lancet 2003;361(9371):1801-9
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001;344(23):1773-9
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia 2013;19(4):499-502
   PubMed Web of Science ®Google Scholar
• Tagariello G, Iorio A, Santagostino E, et al. Italian Association Hemophilia Centre. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009;114(4):779-84
   PubMed Web of Science ®Google Scholar
• Nagel K, Walker I, Decker K, et al. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011;17(6):872-4
   PubMed Web of Science ®Google Scholar
• Lowe GD, Ludlam CA. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost 2008;6(11):1982-3
   PubMed Web of Science ®Google Scholar
• Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012;379(9824):1447-56
   PubMed Web of Science ®Google Scholar
• Franchini M, Frattini F, Crestani S, Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother 2012;13(14):2053-63
   PubMed Web of Science ®Google Scholar
• Franchini M, Frattini F, Crestani S, et al. Treatment of hemophilia B: focus on recombinant factor IX. Biologics 2013;7:33-8
   PubMedGoogle Scholar
• Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008;14(Suppl 3):10-18
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost 2003;1(7):1349-55
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M. Present and future challanges in the treatment of haemophilia: a clinician’s perspective. Blood Transfus 2013;11(Suppl 4):s77-81
   PubMed Web of Science ®Google Scholar
• Pipe SW. Recombinant clotting factors. Thromb Haemost 2008;99(5):840-50
   PubMed Web of Science ®Google Scholar
• Monahan PE, Di Paola J. Recombinant factor IX for clinical and research use. Semin Thromb Hemost 2010;36(5):498-509
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005;105(2):518-25
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001;7(2):133-9
   PubMed Web of Science ®Google Scholar
• Ewenstein BM, Joist JH, Shapiro AD, et al. Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002;42(2):190-7
   PubMed Web of Science ®Google Scholar
• Kisker CT, Eisberg A, Schwartz B; Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003;9(3):279-84
   PubMed Web of Science ®Google Scholar
• Recht M, Pollmann H, Tagliaferri A, et al. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011;17(3):494-9
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010;16(3):437-46
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010;148(4):522-33
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Report on the annual global survey 2012. World Federation of Hemophilia, Montreal; 2011
   Google Scholar
• Santagostino E. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications. Haemophilia 2010;16(Suppl 6):13-17
   PubMed Web of Science ®Google Scholar
• Scalone L. Investing in hemophilia care: benefits and costs for patients and society. Semin Hematol 2008;45(2 Suppl 1):S31-4
   PubMed Web of Science ®Google Scholar
• Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004;18(2):101-13
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003;9(Suppl 1):101-10
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232(1):25-32
   PubMed Web of Science ®Google Scholar
• Poon MC, Aledort LM, Anderle K, et al. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995;35(4):319-23
   PubMed Web of Science ®Google Scholar
• Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013;13:1287-97
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013;11(Suppl 1):84-98
   PubMed Web of Science ®Google Scholar
• Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010;2010:203-9
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345(4):248-55
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22(5):315-29
   PubMed Web of Science ®Google Scholar
• Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010;115:2057-64
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012;119:666-72
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369:2313-23
   PubMed Web of Science ®Google Scholar
• Pasi J, Ragni M, Ozelo M, et al. Recombinant factor IX Fc fusion protein as episodic treatment for bleeding: analysis from the B-LONG study. Hemophilia 2014;20(Suppl 3):15-16
   Google Scholar
• Powell J, Apte S, Chambost H, et al. Long-lasting recombinant factor FIX. Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. J Thromb Haemost 2013;11(Suppl 2):358
   Google Scholar
• Li S, Diao L, Powell J, et al. Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients. J Thromb Haemost 2013;11(Suppl 2):358
   Google Scholar
• ClinicalTrials.gov. Study of recombinant coagulation factor IX Fc fusion protein, BIIB 029, in Pediatric PTP Subjects With Hemophilia B. Available from: http://clinicaltrials.gov/show/NCT01440946 [ Updated 12 September 2013]
   Google Scholar
• ClinicalTrials.gov. Long-term safety and efficacy of recombinant human coagulation factor IX Fusion Protein (rFIXFc) in the prevention and treatment of bleeding episodes in previously treated subjects with hemophilia B (B-YOND). Available from: http://clinicaltrials.gov/show/NCT0142 5723 [Last updated 12 September 2013]
   Google Scholar
• Sheffield WP, Mamdani A, Hortelano G, et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004;126:565-73
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009;102:634-44
   PubMed Web of Science ®Google Scholar
• Nolte MW, Nichols TC, Mueller-Cohrs J, et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost 2012;10:1591-9
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11
   PubMed Web of Science ®Google Scholar
• Santagostino E. PROLONG-9FP clinical development program - phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2013;131(Suppl 2):S7-10
   PubMedGoogle Scholar
• Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res 2013;131(Suppl 2):S11-14
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Lubetsky A, Santagostino E, et al. Efficacy, PK and safety results of a Phase I/II clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B [abstract OC 70.2]. J Thromb Haemost 2013;11(Suppl 2):240-1
   Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011;118(10):2695-701
   PubMed Web of Science ®Google Scholar
• Ostergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011;118(8):2333-41
   PubMed Web of Science ®Google Scholar
• Collins PW, Moss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012;10(11):2305-12
   PubMed Web of Science ®Google Scholar
• Collins PW, Colberg T, Young G, et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B [abstract AS 12.4]. J Thromb Haemost 2013;11(Suppl 2):19
   Google Scholar
• Hart G, Monahan P, Seligsohn U, et al. FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in hemophilic animal models [abstract PO-TU-025]. Haemophilia 2012;18(Suppl 3):32
   Google Scholar
• Bolt G, Bjelke JR, Hermit MB, et al. Hyperglycosylation prolongs the circulation of coagulation factor IX. J Thromb Haemost 2012;10(11):2397-8
   PubMed Web of Science ®Google Scholar
• Hubbard AR. International biological standards for coagulation factors and inhibitors. Semin Thromb Hemost 2007;33(3):283-9
   PubMed Web of Science ®Google Scholar
• Hubbard AR, Dodt J, Lee T, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013;11(5):988-9
   PubMedGoogle Scholar